STOCK TITAN

CervoMed to Deliver Oral Presentation at the 8th International Lewy Body Dementia Conference

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags

CervoMed (NASDAQ: CRVO) announced it will present detailed safety and efficacy results from its RewinD-LB Phase 2b clinical trial of neflamapimod in dementia with Lewy bodies (DLB) at the International Lewy Body Dementia Conference in January 2025. The company expects to release topline data from the study in December 2024. The presentation will take place during the Therapeutics in DLB session on January 31, 2025.

CEO John Alam expressed confidence in the trial design's ability to detect statistically significant and clinically meaningful differences between neflamapimod and placebo, noting there are currently no approved therapies for DLB.

CervoMed (NASDAQ: CRVO) ha annunciato che presenterà risultati dettagliati sulla sicurezza e l'efficacia del suo trial clinico RewinD-LB di fase 2b per il neflamapimod nella demenza con corpi di Lewy (DLB) alla Conferenza Internazionale sulla Demenza con Corpi di Lewy nel gennaio 2025. L'azienda prevede di rilasciare i dati preliminari dello studio a dicembre 2024. La presentazione avverrà durante la sessione Terapie nella DLB il 31 gennaio 2025.

Il CEO John Alam ha espresso fiducia nella capacità del design dello studio di rilevare differenze statisticamente significative e clinicamente rilevanti tra neflamapimod e placebo, sottolineando che attualmente non ci sono terapie approvate per la DLB.

CervoMed (NASDAQ: CRVO) anunció que presentará resultados detallados sobre la seguridad y eficacia de su ensayo clínico RewinD-LB de fase 2b de neflamapimod en la demencia con cuerpos de Lewy (DLB) en la Conferencia Internacional sobre la Demencia con Cuerpos de Lewy en enero de 2025. La empresa espera liberar datos preliminares del estudio en diciembre de 2024. La presentación se llevará a cabo durante la sesión de Terapias en DLB el 31 de enero de 2025.

El CEO John Alam expresó confianza en la capacidad del diseño del ensayo para detectar diferencias estadísticamente significativas y clínicamente relevantes entre neflamapimod y placebo, señalando que actualmente no hay terapias aprobadas para la DLB.

CervoMed (NASDAQ: CRVO)는 2025년 1월에 열리는 국제 루이체 치매 컨퍼런스에서 루이체 치매(DLB)에서의 neflamapimod에 대한 RewinD-LB 2b 임상 시험의 안전성과 유효성에 대한 자세한 결과를 발표할 것이라고 발표했습니다. 회사는 2024년 12월에 연구에 대한 탑라인 데이터를 공개할 것으로 예상하고 있습니다. 발표는 2025년 1월 31일 DLB 치료 세션 중에 진행될 예정입니다.

CEO John Alam은 임상시험 설계가 neflamapimod와 위약 간의 통계적으로 유의미하고 임상적으로 중요한 차이를 탐지할 수 있는 능력에 대한 자신감을 표명하며, 현재 DLB에 대한 승인된 치료법이 없음을 언급했습니다.

CervoMed (NASDAQ: CRVO) a annoncé qu'il présentera des résultats détaillés sur la sécurité et l'efficacité de son essai clinique RewinD-LB de phase 2b de neflamapimod dans la démence à corps de Lewy (DLB) lors de la Conférence internationale sur la démence à corps de Lewy en janvier 2025. L'entreprise prévoit de publier les données préliminaires de l'étude en décembre 2024. La présentation aura lieu lors de la séance sur les thérapies dans la DLB le 31 janvier 2025.

Le PDG John Alam a exprimé sa confiance dans la capacité du design de l'essai à détecter des différences statistiquement significatives et cliniquement pertinentes entre neflamapimod et placebo, notant qu'il n'existe actuellement aucune thérapie approuvée pour la DLB.

CervoMed (NASDAQ: CRVO) kündigte an, dass es detaillierte Sicherheits- und Wirksamkeitsdaten aus seiner RewinD-LB Phase 2b klinischen Studie zu Neflamapimod bei Demenz mit Lewy-Körpern (DLB) auf der Internationalen Lewy-Körper-Demenz-Konferenz im Januar 2025 präsentieren wird. Das Unternehmen erwartet, dass die Topline-Daten aus der Studie im Dezember 2024 veröffentlicht werden. Die Präsentation findet am 31. Januar 2025 in der Sitzung Therapien bei DLB statt.

CEO John Alam äußerte sich zuversichtlich, dass das Studiendesign in der Lage ist, statistisch signifikante und klinisch relevante Unterschiede zwischen Neflamapimod und Placebo festzustellen, und wies darauf hin, dass es derzeit keine zugelassenen Therapien für DLB gibt.

Positive
  • Clinical trial results for potential first-in-class DLB treatment to be presented at major conference
  • Company positioned to address unmet medical need with no currently approved therapies for DLB
Negative
  • None.

Insights

This news about an upcoming conference presentation is not impactful for immediate investment decisions. While the company mentions they are expecting topline data from their Phase 2b RewinD-LB study in December 2024, this announcement is merely about a future presentation of those results at a conference in January 2025. The actual data and trial results are not disclosed in this announcement.

The only noteworthy point is the confirmation of the December 2024 timeline for topline results, but this was likely already known to the market. Investors should wait for the actual Phase 2b results in December 2024 before making any investment decisions based on this clinical program.

Topline data from the RewinD-LB Phase 2b study on track for December 2024

Detailed safety and efficacy data from RewinD-LB Phase 2b study to be featured in an oral presentation at the ILBDC conference in January 2025

BOSTON, Oct. 29, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical-stage company focused on developing treatments for age-related neurologic disorders, today announced that it will deliver an oral presentation providing detailed safety and efficacy results from its completed RewinD-LB Phase 2b clinical trial of neflamapimod in dementia with Lewy bodies (DLB) at the eighth International Lewy Body Dementia Conference (ILBDC) taking place on January 29-31, 2025 in Amsterdam, the Netherlands.

“As we await topline results from the RewinD-LB Phase 2b trial in DLB, we are extremely encouraged by the scientific community’s interest in the data and pleased to have an opportunity to present them at the leading scientific conference dedicated to Lewy Body Dementia,” said John Alam, MD, Chief Executive Officer of CervoMed. “There are currently no approved therapies for DLB, and the dementia clinical research community has a strong interest in the ongoing RewinD-LB Phase 2b study and its potential beneficial impact to patients and families. Topline results for RewinD-LB are expected to be disclosed in December 2024 and we are also presenting data on RewinD-LB baseline patient characteristics at the upcoming Clinical Trials on Alzheimer's Disease Conference (CTAD). Based on our preliminary analyses, we are confident that we have optimized RewinD-LB trial design to detect a statistically significant and clinically meaningful difference between neflamapimod and placebo.”

Details of the ILBDC presentation are as follow:

Abstract Title: Efficacy and safety results of the RewinD-LB phase 2b clinical trial of neflamapimod in dementia with Lewy bodies (DLB)
Format: Oral Presentation
Session Name: Therapeutics in DLB
Session Date and Time: Friday, January 31, 2025, 14.00-15.30 pm Local Time

About CervoMed

CervoMed Inc. (the “Company”) is a clinical-stage company focused on developing treatments for age-related neurologic disorders. The Company is currently developing neflamapimod, an investigational, orally administered small molecule brain penetrant that inhibits p38 mitogen-activated protein kinase alpha. Neflamapimod has the potential to treat synaptic dysfunction, the reversible aspect of the underlying neurodegenerative processes that causes disease in DLB and certain other major neurological disorders. Neflamapimod is currently being evaluated in a Phase 2b study in patients with early-stage DLB.

Forward-Looking Statements

This press release includes express and implied forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, regarding the intentions, plans, beliefs, expectations or forecasts for the future of the Company, including, but not limited to, the therapeutic potential of neflamapimod and the anticipated timing and achievement of clinical and development milestones, including the completion and achievement of primary endpoints of the RewinD-LB Phase 2b clinical trial and the Company’s announcement of topline and other data therefrom. Terms such as “believes,” “estimates,” “anticipates,” “expects,” “plans,” “aims,” “seeks,” “intends,” “may,” “might,” “could,” “might,” “will,” “should,” “approximately,” “potential,” “target,” “project,” “contemplate,” “predict,” “forecast,” “continue,” or other words that convey uncertainty of future events or outcomes (including the negative of these terms) may identify these forward-looking statements. Although there is believed to be reasonable basis for each forward-looking statement contained herein, forward-looking statements by their nature involve risks and uncertainties, known and unknown, many of which are beyond the Company’s control and, as a result, actual results could differ materially from those expressed or implied in any forward-looking statement. Particular risks and uncertainties include, among other things, those related to: the Company’s available cash resources and the availability of additional funds on acceptable terms; the results of the Company’s clinical trials, including RewinD-LB; the likelihood and timing of any regulatory approval of neflamapimod or the nature of any feedback the Company may receive from the U.S. Food and Drug Administration; the ability to implement business plans, forecasts, and other expectations in the future; general economic, political, business, industry, and market conditions, inflationary pressures, and geopolitical conflicts; and the other factors discussed under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023 filed with the U.S. Securities and Exchange Commission (SEC) on March 29, 2024, and other filings that the Company may file from time to time with the SEC. Any forward-looking statements in this press release speak only as of the date hereof (or such earlier date as may be identified). The Company does not undertake any obligation to update such forward-looking statements to reflect events or circumstances after the date of this press release, except to the extent required by law.

Investor Contact:

PJ Kelleher
LifeSci Advisors
Investors@cervomed.com
617-430-7579


FAQ

When will CervoMed (CRVO) release topline data for the RewinD-LB Phase 2b trial?

CervoMed (CRVO) will release topline data from the RewinD-LB Phase 2b trial in December 2024.

When will CervoMed (CRVO) present the detailed RewinD-LB Phase 2b trial results?

CervoMed will present detailed results at the International Lewy Body Dementia Conference on January 31, 2025, in Amsterdam.

What is the purpose of CervoMed's (CRVO) RewinD-LB Phase 2b trial?

The RewinD-LB Phase 2b trial evaluates neflamapimod as a potential treatment for dementia with Lewy bodies (DLB), a condition that currently has no approved therapies.

CervoMed Inc.

NASDAQ:CRVO

CRVO Rankings

CRVO Latest News

CRVO Stock Data

105.40M
8.25M
35.2%
42.09%
15.38%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
BOSTON